Document:

<PAGE>
                                                                   Exhibit 10.30

Mr. Jonah Shacknai
Chairman and CEO
Medicis Pharmaceutical Corp.
8125 North Hayden Road
Scottsdale, AZ 85258

March 18, 2005

Dear Jonah:

          We acknowledge your February 9, 2005 letter, informing us of the
pending transactions between Medicis Pharmaceutical Corp. ("Medicis") and Inamed
Corporation ("Inamed"), through which the businesses of Medicis and Inamed will
be combined and Medicis will continue as the surviving entity (the
"Acquisition").

          We further acknowledge your request that we agree to waive certain of
our rights under the Restylane and Sub-Q agreements between our companies in
order to enable you to consummate the Acquisition.

          In light of the foregoing and upon the conditions set forth in this
letter, for good and valuable consideration, the receipts, sufficiency and
adequacy of which are hereby acknowledged, each party, on behalf of itself and
its affiliates, hereby agrees as follows:

     1. Upon the closing of the Acquisition, Q-Med agrees that, for a period of
24 months following the closing of the Acquisition, it shall have no rights to
enforce the non-competition provisions embodied in Section 7.4(b) of the
Restylane Supply Agreement, entered into as of March 7, 2003 or the diligence
obligations embodied in Section 3.1 of the Restylane Amended and Restated
License Agreement, entered into as of March 6, 2003.

     2. Following the closing of the Acquisition, Medicis shall operate the
competing Inamed business only (i) in accordance with an agreement reached with
Q-Med no later than six (6) months from the closing of the Acquisition (see
below), or (ii) subject to a divestiture or wind-up plan pursuant to which,
immediately upon closing of the Acquisition, the competing activities will be
operated and managed independently and disposed of as soon as reasonably
practicable.

     3. Medicis and Q-Med shall work diligently to reach a comprehensive
agreement regarding: (a) operation of the Inamed business outside Canada and the
U.S. (and its territories); (b) sales of Inamed products outside Canada and the
U.S. (and its territories); (c) global strategic alliance and collaboration
between Medicis and Q-Med on its Restylane products; and (d) amendment of the
existing Restylane agreements to reflect
<PAGE>
the new scope of Medicis' business both inside Canada and the U.S. (and its
territories) as well as outside of Canada and the U.S. (and its territories).
The parties shall devote all necessary resources so that an agreement in
principle or a term sheet and amendment shall be executed no later than six (6)
months after the closing of the Acquisition and failing which, the royalty set
forth in paragraph 4, below, shall commence to apply.

     4. If the comprehensive agreement and amendment referred to in paragraph 3
are not executed within six (6) months from the closing of the Acquisition,
thereafter Medicis shall pay to Q-Med an ongoing royalty of l5% on net revenues
of Inamed products (including products that Inamed is licensed to sell, whether
or not it manufactures them) that compete with Q-Med products outside the U.S.
and Canada (including expressly, but without limitation, Hylaform, Zyplast and
Zyderm), until the competing activities are divested or discontinued. Q-Med
shall have a right to audit the records of Medicis on an annual basis to ensure
compliance with this provision.

     5. Medicis' option to obtain a manufacturing license under the Restylane
Supply Agreement (Section 10.1 of the Restylane Supply Agreement) shall be
delayed for the same period as the length of time between the date hereof and
execution of the definitive agreements referred to in paragraph 3 above
(including amendment of the existing Restylane agreement), subject to a maximum
of 24 months. Medicis hereby agrees that Purchaser shall not have any right to
deliver the Exercise Notice prior to the date determined in accordance with the
preceding sentence (capitalized terms as defined in the Restylane Supply
Agreement).

     6. Medicis shall use the trademark RESTYLANE only in connection with
products manufactured in accordance with one or more Licensed Patents (as
defined in the Restylane Amended and Resisted Intellectual Property License
Agreement of March 6, 2003).

     7. Q-Med shall have a right to review, and Medicis shall cooperate with
Q-Med regarding, any press release announce in connection with the Acquisition
that mentions "Q-Med," "Restylane" or Sub-Q."

     8. Within five (5) business days after execution of the contemplated
Acquisition transaction documents the parties shall file motions to dismiss with
prejudice (a) the investigation pending in the U.S. International Trade
Commission, captioned as In re Certain Injectable Implant Compositions, Inv. No.
337-TA-515, between Inamed as complainant and Q-Med and Medicis as respondents
and (b) the litigation pending in the U.S. District Court for the Southern
District of California, captioned as Inamed Corp., v. Q-Med AB, et al, No.
3:04-CV-1064, between Inamed as plaintiff and Q-Med and Medicis as defendants,
and shall take all appropriate actions to ensure that such investigations and
such litigation are dismissed with prejudice within thirty (30) days after
filing of such motions.

     9. If the Acquisition fails to close for any reason that would give rise to
Medicis' obligation to pay Inamed an expense or termination fee pursuant to
Section 5.10(o) of the Agreement and Plan of Merger between Medicis and Inamed,
<PAGE>
Medicis will pay to Inamed the aggregate sum of Sixteen Million Five Hundred
Thousand dollars ($l6,500,000) in consideration of Inamed's dismissal of the
U.S. International Trade Commission investigation and the litigation as
described in paragraph 8 above. Medicis and its affiliates shall not make any
claim against Q-Med and its affiliates for recovery of all or any portion of
this amount under the indemnification provisions of the Restylane agreements' or
otherwise.

          It should be understood that until we are informed of the exact
structure that Acquisition will take, we are unable to determine whether the
Acquisition constitutes a change of control or triggers any of the assignment
provisions under the Restylane Agreements. For the purposes of this letter, we
have assumed that the Acquisition does not constitute a change of control
situation and that any assignment or transfer of rights licensed from Q-Med is
to a Permitted Transferee. The consent contemplated hereby shall not be
effective if the transaction between Medicis and Inamed involves such a change
of control.

          Further, at present, we do not believe that the non-compete and
diligence obligations in the Sub-Q Agreements would be triggered at the time of
closing the Acquisition. Accordingly, Q-Med's agreement above to suspend
enforcement of the non-compete and diligence obligations applies only to those
covenants and obligations in the Restylane Agreements.

          Notwithstanding anything in this letter to the contrary, other than
the obligation set forth in paragraphs 7, 8 and 9 of this letter, the rights and
obligations of the parties set forth in this letter shall not be binding or
shall be of no force or effect if the Acquisition is not consummated.

          Kindly affirm your agreement with the foregoing by signing below,

/s/ Bengt Agerup                        /s/ Jonah Shacknai
-------------------------------------   ----------------------------------------
Bengt Agerup                            Jonah Shacknai
Q-Med AB                                Medicis Pharmaceutical Corp.

Agreed and Acknowledged:

Inamed Corporation

-------------------------------------
By:
    ---------------------------------
Title:
       ------------------------------
<PAGE>
Medicis will pay to Inamed the aggregate sum of Sixteen Million Five Hundred
Thousand dollars ($l6,500,000) in consideration of Inamed's dismissal of the
U.S. International Trade Commission investigation and the litigation as
described in paragraph 8 above. Medicis and its affiliates shall not make any
claim against Q-Med and its affiliates for recovery of all or any portion of
this amount under the indemnification provisions of the Restylane agreements or
otherwise.

          It should be understood that until we are informed of the exact
structure that Acquisition will take, we are unable to determine whether the
Acquisition constitutes a change of control or triggers any of the assignment
provisions under the Restylane Agreements. For the purposes of this letter, we
have assumed that the Acquisition does not constitutes a change of control
situation and that any assignment or transfer of rights licensed from Q-Med is
to a Permitted Transferee. The consent contemplated hereby shall not be
effective if the transaction between Medicis and Inamed involves such a change
of control.

          Further, at present, we do not believe that the non-compete and
diligence obligations in the Sub-Q Agreements would be triggered at the time of
closing the Acquisition. Accordingly, Q-Med's agreement above to suspend
enforcement of the non-compete and diligence obligations applies only to those
covenants and obligations in the Restylane Agreements.

          Notwithstanding anything in this letter to the contrary, other than
the obligation set forth in paragraphs 7, 8 and 9 of this letter, the rights and
obligations of the parties set forth in this letter shall not be binding or
shall be of no force or effect if the Acquisition is not consummated.

          Kindly affirm your agreement with the foregoing by signing below.

/s/ Bengt Agerup
-------------------------------------   ----------------------------------------
Bengt Agerup                            Jonah Shacknai
Q-Med AB                                Medicis Pharmaceutical Corp.

Agreed and Acknowledged:

Inamed Corporation

/s/ Illegible
-------------------------------------
By:
    ---------------------------------
Title:
       ------------------------------exv10w1

 

Exhibit
10.1

AMENDMENT NO. 6 TO

RECEIVABLES SALE AGREEMENT

     This Amendment No. 6 to Receivables Sale Agreement (this “Amendment”) is entered into
as of August 3, 2005, between Avnet, Inc., a New York corporation (“Originator”), and Avnet
Receivables Corporation, a Delaware corporation (“Buyer”).

RECITALS

     Originator and Buyer entered into that certain Receivables Sale Agreement, dated as of June
28, 2001, and amended such Receivables Sale Agreement pursuant to Amendment No. 1 thereto, dated as
of February 6, 2002, and further amended such Receivables Sale Agreement pursuant to Amendment No.
2 thereto, dated as of June 26, 2002, and further amended such Receivables Sale Agreement pursuant
to Amendment No. 3 thereto, dated as of November 25, 2002, and further amended such Receivables
Sale Agreement pursuant to Amendment No. 4 thereto, dated as of December 12, 2002, and further
amended such Receivables Sale Agreement pursuant to Amendment No. 5 thereto, dated as of August 15,
2003 (such agreement, as so amended, the “Sale Agreement”).

     Avnet Receivables Corporation, as Seller, Avnet, Inc., as Servicer, the Financial Institutions
party thereto, the Companies party thereto and JPMorgan Chase Bank, N.A. (successor by merger to
Bank One, NA (Main Office Chicago)), as agent, are entering into Amendment No. 7 to Amended and
Restated Receivables Purchase Agreement, dated as of the date hereof (the “RPA Amendment”).

     Each of the parties hereto now desires to amend the Sale Agreement, subject to the terms and
conditions hereof, to, among other things, conform the Sale Agreement with the amendments
contemplated by the RPA Amendment, as more particularly described herein.

AGREEMENT

     NOW, THEREFORE, in consideration of the premises, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto
hereby agree as follows:

 

 

     Section 1. Definitions Used Herein. Capitalized terms used herein and not otherwise
defined herein shall have the respective meanings set forth for such terms in, or incorporated by
reference into, the Sale Agreement.

     Section 2. Amendments. Subject to the terms and conditions set forth herein, the
Sale Agreement is hereby amended as follows:

          (a) Section 2.1(o) of the Sale Agreement is hereby amended by deleting the phrase “(other
than a Permitted Adverse Claim)” from the end of the first sentence in such section.

          (b) Section 4.1(l) of the Sale Agreement is hereby amended by replacing the phrase “Upon the
request of the Agent or Scotia” in such section with the phrase “Upon the request of the Agent or
any Financial Institution”.

          (c) Section 4.2(d) of the Sale Agreement is hereby amended by (i) deleting the following
phrase “; provided that, after the Termination Date, Originator may grant or create a
Permitted Adverse Claim upon any Receivable arising after the Termination Date, together with any
Collections and Related Security with respect to any such Receivable arising after the Termination
Date” from the end of the first sentence in such section and (ii) deleting the following phrase “,
other than a Permitted Adverse Claim; provided that such Permitted Adverse Claim does not
create or suffer to exist any Adverse Claim on or with respect to (i) the proceeds of any inventory
which proceeds constitute Receivables, Related Security or Collections or (ii) any returned or
repossessed inventory or goods the sale, lease or financing of which gave rise to any Receivable”
from the end of the last sentence in such section.

          (d) Section 5.1(f) of the Sale Agreement is hereby amended and restated in its entirety to
read as follows:

     (f) (i) the “Consolidated Interest Coverage Ratio” (as defined in the Current
Avnet Credit Agreement) as of the end of any period of four fiscal quarters of
Avnet shall be less than 3.00 to 1.00 or (ii) the “Consolidated Leverage Ratio”
(as defined in the Current Avnet Credit Agreement) at any time during any period
set forth below shall be greater than the ratio set forth below opposite such
period:

2

 

	 	 	 	 	 
	 	 	Maximum Consolidated
	Period	 	Leverage Ratio
	April 3, 2005 through
July 2, 2005
	 	 	5.00 to 1.00	 
	July 3, 2005 through
October 1, 2005
	 	 	4.75 to 1.00	 
	October 2, 2005 through
December 31, 2005
	 	 	4.50 to 1.00	 
	January 1, 2006 through
July 1, 2006
	 	 	4.25 to 1.00	 
	July 2, 2006 and thereafter
	 	 	4.00 to 1.00	 

          (e) Section 7.4(b) of the Sale Agreement is hereby amended by replacing the phrase “Bank One
or Scotia acts as the administrative agent” in such section with the phrase “the Agent or any
Financial Institution acts as the administrative agent”.

     Section 3. Conditions to Effectiveness of Amendment. This Amendment shall become
effective as of the date hereof, upon the satisfaction of the conditions precedent that:

          (a) Amendment. The Buyer and the Agent shall have received, on or before the date
hereof, executed counterparts of this Amendment, duly executed by each of the parties hereto.

          (b) RPA Amendment. All conditions precedent contained in Section 5 of the RPA
Amendment shall have been satisfied and the RPA Amendment shall be in full force and effect.

          (c) Representations and Warranties. As of the date hereof, both before and after
giving effect to this Amendment, all of the representations and warranties contained in the Sale
Agreement and in each other Transaction Document shall be true and correct as though made on and as
of the date hereof (and by its execution hereof, each of Buyer and Originator shall be deemed to
have represented and warranted such).

          (d) No Termination Event or Potential Termination Event. As of the date
hereof, both before and after giving effect to this Amendment, no

3

 

Termination Event or Potential Termination Event shall have occurred and be continuing (and by
its execution hereof, Buyer and Originator shall be deemed to have represented and warranted such).

          Section 4. Miscellaneous.

               (a) Effect; Ratification. The
amendments set forth herein are effective solely for the purposes set forth herein and shall be
limited precisely as written, and shall not be deemed (i) to be a consent to any amendment, waiver
or modification of any other term or condition of the Sale Agreement or of any other instrument or
agreement referred to therein or (ii) to prejudice any right or remedy which Buyer (or any of its
assigns) may now have or may have in the future under or in connection with the Sale Agreement, as
amended hereby, or any other instrument or agreement referred to therein. Each reference in the
Sale Agreement to “this Agreement,” “herein,” “hereof” and words of like import and each reference
in the other Transaction Documents to the Sale Agreement, to the “Receivables Sale Agreement” or to
the “Sale Agreement” shall mean the Sale Agreement as amended hereby. This Amendment shall be
construed in connection with and as part of the Sale Agreement and all terms, conditions,
representations, warranties, covenants and agreements set forth in the Sale Agreement and each
other instrument or agreement referred to therein, except as herein amended, are hereby ratified
and confirmed and shall remain in full force and effect.

               (b) Transaction Documents. This Amendment is a
Transaction Document executed pursuant to the Sale Agreement and shall be construed, administered
and applied in accordance with the terms and provisions thereof.

               (c) Costs, Fees and Expenses. Without limiting Section 6.2 of the Sale Agreement, Originator agrees to reimburse
Buyer and its assigns upon demand for all reasonable and documented out-of-pocket costs, fees and
expenses in connection with the preparation, execution and delivery of this Amendment (including
the reasonable fees and expenses of counsels to Buyer and its assigns).

               (d) Counterparts. This Amendment may
be executed in any number of counterparts, each such counterpart constituting an original and all
of which when taken together shall constitute one and the same instrument.

               (e) Severability. Any
provision contained in this Amendment which is held to be inoperative, unenforceable or invalid in
any jurisdiction shall, as 

4

 

to that jurisdiction, be inoperative, unenforceable or invalid without
affecting the remaining provisions of this Amendment in that jurisdiction or the operation,
enforceability or validity of such provision in any other jurisdiction.

          (f) GOVERNING LAW. THIS AMENDMENT
SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK EXCLUDING
CHOICE-OF-LAW PRINCIPLES OF THE LAW OF SUCH STATE THAT WOULD REQUIRE THE APPLICATION OF THE LAWS OF
A JURISDICTION OTHER THAN SUCH STATE.

          (g) WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES TRIAL BY JURY IN ANY
JUDICIAL PROCEEDING INVOLVING, DIRECTLY OR INDIRECTLY, ANY MATTER (WHETHER SOUNDING IN TORT,
CONTRACT OR OTHERWISE) IN ANY WAY ARISING OUT OF, RELATED TO, OR CONNECTED WITH THIS AMENDMENT, ANY
DOCUMENT EXECUTED BY ORIGINATOR PURSUANT TO THIS AMENDMENT OR THE RELATIONSHIP ESTABLISHED
HEREUNDER OR THEREUNDER

(Signature
Page Follows)

5

 

          IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered
by their respective duly authorized officers as of the date first written above.

	 	 	 	 	 
	 	AVNET, INC.

 	 
	 	By: 	 /s/
Raymond Sadowski	 
	 	Name: 	 Raymond Sadowski	 
	 	Title: 	 Sr. Vice President,
Chief Financial Officer and Assistant Secretary	 
	 
	 	AVNET RECEIVABLES CORPORATION

 	 
	 	By:  	 /s/ Raymond Sadowski	 
	 	Name:  	 Raymond Sadowski	 
	 	Title:  	 President and Treasurer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]